Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomy.

Beyeler, Morin; Rea, Erich; Weber, Loris; Belachew, Nebiyat Filate; Barvulsky Aleman, Enrique; Kielkopf, Moritz; Kurmann, Christoph C; Grunder, Lorenz; Piechowiak, Eike Immo I; Meinel, Thomas R; Heldner, Mirjam R; Seiffge, David; Pilgram-Pastor, Sara; Dobrocky, Tomas; Pabst, Thomas; Berger, Martin D; Jung, Simon; Arnold, Marcel; Gralla, Jan; Fischer, Urs; ... (2023). Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomy. (In Press). Journal of neurointerventional surgery BMJ Publishing Group 10.1136/jnis-2023-020793

[img] Text
jnis-2023-020793.full.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (1MB) | Request a copy


The absence of the susceptibility vessel sign (SVS) in patients treated with mechanical thrombectomy (MT) is associated with poor radiological and clinical outcomes after 3 months. Underlying conditions, such as cancer, are assumed to influence SVS status and could potentially impact the long-term outcome. We aimed to assess SVS status as an independent predictor of long-term outcomes in MT-treated patients.


SVS status was retrospectively determined in consecutive MT-treated patients at a comprehensive stroke center between 2010 and 2018. Predictors of long-term mortality and poor functional outcome (modified Rankin Scale (mRS) ≥3) up to 8 years were identified using multivariable Cox and logistic regression, respectively.


Of the 558 patients included, SVS was absent in 13% (n=71) and present in 87% (n=487) on baseline imaging. Patients without SVS were more likely to have active cancer (P=0.003) and diabetes mellitus (P<0.001) at the time of stroke. The median long-term follow-up time was 1058 days (IQR 533-1671 days). After adjustment for active cancer and diabetes mellitus, among others, the absence of SVS was associated with long-term mortality (adjusted HR (aHR) 2.11, 95% CI 1.35 to 3.29) and poor functional outcome in the long term (adjusted OR (aOR) 2.90, 95% CI 1.29 to 6.55).


MT-treated patients without SVS have higher long-term mortality rates and poorer long-term functional outcome. It appears that this association cannot be explained by comorbidities alone, and further studies are warranted.

Item Type:

Journal Article (Original Article)


04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology
04 Faculty of Medicine > Department of Radiology, Neuroradiology and Nuclear Medicine (DRNN) > Institute of Diagnostic and Interventional Neuroradiology
04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Medical Oncology

Graduate School:

Graduate School for Health Sciences (GHS)

UniBE Contributor:

Beyeler, Morin, Belachew, Nebiyat Filate, Kielkopf, Moritz Christopher, Kurmann, Christoph Carmelino, Grunder, Lorenz Nicolas, Piechowiak, Eike Immo, Meinel, Thomas Raphael, Heldner, Mirjam Rachel, Seiffge, David Julian, Pilgram-Pastor, Sara Magdalena, Dobrocky, Tomas, Pabst, Thomas Niklaus, Berger, Martin Dave, Jung, Simon, Arnold, Marcel, Gralla, Jan, Fischer, Urs Martin, Kaesmacher, Johannes, Mujanović, Adnan


600 Technology > 610 Medicine & health




BMJ Publishing Group




Pubmed Import

Date Deposited:

03 Nov 2023 10:31

Last Modified:

03 Nov 2023 19:14

Publisher DOI:


PubMed ID:


Uncontrolled Keywords:

MRI neoplasm stroke thrombectomy




Actions (login required)

Edit item Edit item
Provide Feedback